Leerink Swann covered Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), hiking its target to $211.00 earlier today
- Updated: September 26, 2016
Yesterday Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) traded -0.80% lower at $125.77. ALXN’s 50-day average is $130.81 and its two hundred day average is $135.64. With the last stock price down -6.96% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the date range. 261,920 shares of Alexion Pharmaceuticals Inc. exchanged hands, down from an avg. volume of 1,722,460
In a report released on 9/26/2016 Leerink Swann increased the target of Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) from $210.00 to $211.00 stating a potential upside of 0.68%.
Previously on 09/23/2016, Jefferies & Co reported about Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) bumped down the target price from $140.00 to $120.00 that suggested a downside of -0.06%.
Recent Performance Chart
Alexion Pharmaceuticals Inc. has P/E ratio of 317.09 with a 52 week low of $110.56 and a one year high of $193.45 and has a total market value of $0.
In addition to Leerink Swann reporting its stock price target, a total of 18 equity analysts have released a ratings update on Alexion Pharmaceuticals Inc.. The 12-month price target is $187.61 with seven brokerages rating the stock a strong buy, 6 firms rating the stock a buy, 7 equity analysts rating the company a hold, zero firms rating the stock a underperform, and finally zero analysts rating the stock a sell.
Brief Synopsis On Alexion Pharmaceuticals Inc. (NASDAQ:ALXN)
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company's marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company's clinical programs include Soliris (eculizumab), ALXN 1101, ALXN 1007, SBC-103, ALXN 1210 and ALXN 5500. It offers Soliris for patients with either paroxysmal nocturnal hemoglobinuria (PNH), a life-threatening and ultra-rare genetic blood disorder, or atypical hemolytic uremic syndrome (aHUS), a life-threatening and ultra-rare genetic disease. Strensiq is a targeted enzyme replacement therapy. It offers Kanuma for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D). ALXN 1007 is a humanized antibody designed to target inflammatory disorders.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.